10561249

Source:http://linkedlifedata.com/resource/pubmed/id/10561249

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0006142, umls-concept:C0006826, umls-concept:C0008976, umls-concept:C0014582, umls-concept:C0030705, umls-concept:C0034656, umls-concept:C0039286, umls-concept:C0232970, umls-concept:C0282116, umls-concept:C0746319, umls-concept:C1257890, umls-concept:C1512888
pubmed:issue	7
pubmed:dateCreated	2000-6-7
pubmed:abstractText	To assess whether the addition of epirubicin (EPI) therapy to prolonged treatment with tamoxifen (TAM) improves relapse-free and overall survival in postmenopausal women with node-positive primary breast cancer.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8309333
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Hormonal, http://linkedlifedata.com/resource/pubmed/chemical/Epirubicin, http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen
pubmed:status	MEDLINE
pubmed:month	Jul
pubmed:issn	0732-183X
pubmed:author	pubmed-author:BlissJ MJM, pubmed-author:CoombesGG, pubmed-author:CoombesR CRC, pubmed-author:FontaineCC, pubmed-author:MartyMM, pubmed-author:MorvanFF, pubmed-author:OlmosTT, pubmed-author:Pérez-LópezF RFR, pubmed-author:VassilopoulosPP, pubmed-author:WilsJ AJA, pubmed-author:WoodsEE
pubmed:issnType	Print
pubmed:volume	17
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	1988-98
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:10561249-Adult, pubmed-meshheading:10561249-Age Factors, pubmed-meshheading:10561249-Aged, pubmed-meshheading:10561249-Antineoplastic Agents, Hormonal, pubmed-meshheading:10561249-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:10561249-Breast Neoplasms, pubmed-meshheading:10561249-Disease-Free Survival, pubmed-meshheading:10561249-Epirubicin, pubmed-meshheading:10561249-Female, pubmed-meshheading:10561249-Humans, pubmed-meshheading:10561249-London, pubmed-meshheading:10561249-Lymphatic Metastasis, pubmed-meshheading:10561249-Middle Aged, pubmed-meshheading:10561249-Neoplasm Recurrence, Local, pubmed-meshheading:10561249-Neoplasms, Second Primary, pubmed-meshheading:10561249-Paris, pubmed-meshheading:10561249-Postmenopause, pubmed-meshheading:10561249-Proportional Hazards Models, pubmed-meshheading:10561249-Survival Rate, pubmed-meshheading:10561249-Tamoxifen
pubmed:year	1999
pubmed:articleTitle	Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
pubmed:affiliation	Laurentius Hospital, Roermond, The Netherlands.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study